Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12

Cancer Gene Therapy

Volumn 6, Issue 6, 1999, Pages 514-522

  Mazzolini, Guillermo ^a   Qian, Cheng ^a   Xie, Xiaoming ^a   Sun, Yonglian ^a   Lasarte, Juan J ^a   Drozdzik, Marek ^a   Prieto, Jesús ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Adenovirus; Animal model; Colon cancer; Cytotoxicity; Gene therapy; Interleukin 12

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12;

ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL LINE; COLON TUMOR; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; MOUSE;

ADENOVIRIDAE; ANIMALS; CELL LINE; COLONIC NEOPLASMS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033218662     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700072     Document Type: Article

References (53)

1. Cohen AM, Minsky BD, Schilsky RL. Cancer of the colon. In: DeVita T Jr., Hellman S, Rosemberg SA, eds. Cancer. Principles, and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997:1144-1197.
2. Willet CG, Tepper JE, Cohen AM, Orlow E, Welch C. Failure patterns following curative resection of colonic carcinoma. Ann Surg. 1984;200:685-690.
3. Cohen AM, Tremittera S, Candela F, Thaler JT, Sigurdson ER. Prognosis of node-positive colon cancer. Cancer. 1991;67:1859-1861.
4. Ries LA, Miller BA, Hankey BF, Kosary C, Harras A, Edwards B, eds. SEER Cancer Statistics Review, 1973-1991. Bethesda, Md: National Cancer Institute; 1994. National Institutes of Health Publication No. 92-2789.
5. Zier K, Gansbacher B, Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today. 1996;17:39-45.
6. Musiani P, Modesti A, Giovarella M, et al. Cytokine, tumor-cell death, and immunogenicity: a question of choice. Immunol Today. 1997;18:32-36.
7. Schmidt-Wolf G, Schmidt-Wolf GH. Cytokines and gene therapy. Immunol Today. 1995;16:173-175.
8. Colombo M, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today. 1994;15:48-51.
9. Stern LL, Tarby CM, Tamborini B, Truitt GA. Preclinical development of IL-12 as an anticancer drug: comparison to IL-2. Proc Annu Meet Am Assoc Cancer Res. 1994;35: A3100.
10. Lamonta A, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today. 1996;17:214-217.
11. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol. 1991;146:3074-3081.
12. + T cells to enhance priming for IFN-γ production and diminishes IL-4 inhibition of such priming. Proc Natl Acad Sci USA. 1993;90:10188-10192.
13. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ In vivo. Int Immunol 1994;6:157-167.
14. Manetti R, Gerosa F, Giudizi MG, et al. Interleukin-12 induces stable priming for interferon γ (IFN-γ) production during differentiation of human T helper (Th) cells and transient IFN-γ production in established Th2 cell clones. J Exp Med. 1994;179:1273-1283.
15. Trinchieri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol Today. 1993;14:335-338.
16. Hendrzak JA, Brunda MJ. Interleukin 12: biological activity, therapeutic utility, and role in disease. Lab Invest. 1995;72:619-637.
17. Brunda MJ, Luistro LL, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230.
18. Mu J, Zou JP, Yamamoto N, et al. Administration of recombinant interleukin-12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 1995;5:4404-4408.
19. Tannenbaum CS, Wicker N, Armstrong D, et al. Cytokine and chemokine expression in tumors of mice receiving systemic IL-12 therapy. J Immunol. 1996;156:693-699.
20. Noguchi Y, Jungbluth A, Richards E, Old L. Effect of interleukin 12 on tumor induction by 3-methylcolantrene. Proc Natl Acad Sci USA. 1996;93:11798-11801.
21. Brunda MJ, Luistro J, Hendrzak JA, Fountoluakis M, Garotta G, Gately MK. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother. 1995;17:71-77.
22. Orange JS, Salazar-Mather TP, Opal SM, et al. Mechanisms of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med. 1995;181:901-914.
23. Marshall E. Cancer trial of interleukin-12 halted. Science. 1995;268:1555.
24. Jenks S. After initial setback, IL-12 regaining popularity. J Natl Cancer Inst. 1996;88:576-577.
25. Cavallo F, Signorelli P, Giovarelli M, et al. Antitumor efficacy of adenocarcinoma cell engineered to produce interleukin-12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst. 1997;89:1049-1058.
26. Bannei R, Arroyo CD, Cordon-Cardo C, et al. The role of IL-12 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol. 1994; 152:2324-2332.
27. Tahara H, Zeh HJ III, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994;54:182-189.
28. Martinotti A, Stoppacciaro A, Vagliani M, et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol. 1995;25:137-146.
29. Rakhmilevich AL, Turner J, Ford J, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA. 1996;93:6921-6296.
30. Rakhmilevich AL, Janssen K, Turner J, Culp J, Yang N. Cytokine gene therapy using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther. 1997;8:1303-1311.
31. Meko JB, Yim JH, Tsung K, Norton JA. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res. 1995;55:4765-4770.
32. Tan J, Newton CA, Djeu JY, et al. Injection of comple-mentary DNA encoding interleukin-12 inhibits tumor establishment at distant sites in a murine renal carcinoma model. Cancer Res. 1996;56:3399-3403.
33. Caruso M, Pham-Nguyen K, Kwong Y, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA. 1996;93:11302-11306.
34. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and longlasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther. 1996;7: 1995-2202.
35. Chen L, Chen D, Block E, O'Donnell M, Kufe DW, Clinton SK. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol. 1997;159:351-359.
36. Toda M, Martuza RL, Kojima H, Rabkin S. In situ cancer vaccination: an IL-12 defective vector/replication-competent HSV combination induces local and systemic antitumor activity. J Immunol. 1998;160:4457-4464.
37. Blaese M, Blankestein T, Brenner M, et al. Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995;2:291-297.
38. Qian C, Bilbao R, Bruña O, Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology. 1995; 22:118-123.
39. Brattain MG, Strobel-Stevenson J, Find D, Webb M, Sarrif AM. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 1980;40:2142-2146.
40. Corbett TH, Griswald DD, Roberts BJ, Peckham JC, Schabel FM. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assay with a note on carcinogen structure. Cancer Res. 1975;35:2434-2439.
41. Chensue SW, Ruth JH, Warmington K, Lincoln O, Kunkel SL. In vivo regulation of macrophage IL-12 production during type 1 and type 2 cytokine-mediated granuloma formation. J Immunol. 1995;155:3546-3551.
42. Coligan JE, Kruisbeck AM, Marguiles DH, Sevach EM, Strober W. Currents Protocols in Immunology. New York: Wiley-Interscience; 1994:3.11.1-3.11.20.
43. + helper lymphocytes. Res Immunol. 1995;146:35-44.
44. Qian C, Idoate M, Bilbao R, et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitro-samine-induced hepatocellular carcinoma. Hum Gene Ther. 1997;8:349-358.
45. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol. 1994;153: 1697-1706.
46. Murray D, Hreno A, Dutton J, et al. Prognosis in colon cancer: a pathologic reassessment. Arch Surg. 1975;110: 908-913.
47. Pihl E, Malahy MA, Khankhanian N, Hersh EM, Mavligit GM. Immunomorphological features of prognosis significance in Duke's class B colorectal carcinoma. Cancer Res. 1977;37:4145-4149.
48. Fearon ER, Itaya T, Hunt B, Vogelstein B, Frost P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 1988;35:2975-2980.
49. Huang AYC, Gulden PH, Woods MC, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA. 1996;93:9730-9725.
50. Voest EE, Kenyan BM, O'Reilly MS, Truitt G, Damato RJ, Folkman Y. Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst. 1995;8:581-586.
51. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc Natl Acad Sci USA. 1989;86:9456-9460.
52. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol. 1993;11: 571-611.
53. Copeland EM, Miller LD, Jones RS, et al. Prognostic factors in carcinoma of the colon and rectum. Am J Surg. 1968;116:875-881.